Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lynch-like syndrome with germline WRN mutation in Bulgarian patient with synchronous endometrial and ovarian cancer. | Hered Cancer Clin Pract | 2023 | 37452354 | PubTator, text mining | PubMed |
| UBA80 and UBA52 fine-tune RNF168-dependent histone ubiquitination and DNA repair. | J Biol Chem | 2023 | 37451480 | PubTator, text mining | PubMed |
| GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. | Int J Mol Sci | 2023 | 37446056 | PubTator, text mining | PubMed |
| Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches. | Int J Mol Sci | 2023 | 37445860 | PubTator, text mining | PubMed |
| Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. | Cancers (Basel) | 2023 | 37444554 | PubTator, text mining | PubMed |
| Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. | Cancers (Basel) | 2023 | 37444426 | PubTator, text mining | PubMed |
| Payer reimbursement practices and incentives for improving interpretation of germline genetic testing. | J Law Biosci | 2023 | 37435610 | PubTator, text mining | PubMed |
| Impact of DNA damage repair alterations on prostate cancer progression and metastasis. | Front Oncol | 2023 | 37434977 | PubTator, text mining | PubMed |
| Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials. | J Nanobiotechnology | 2023 | 37434199 | PubTator, text mining | PubMed |
| PARP inhibitors: enhancing efficacy through rational combinations. | Br J Cancer | 2023 | 37430137 | PubTator, text mining | PubMed |
| Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability. | Nat Cell Biol | 2023 | 37414849 | PubTator, text mining | PubMed |
| Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. | Genes Dis | 2023 | 37396515 | PubTator, text mining | PubMed |
| Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. | Res Rep Urol | 2023 | 37396015 | PubTator, text mining | PubMed |
| Molecular typing and mutational characterization of rectal neuroendocrine neoplasms. | Cancer Med | 2023 | 37387515 | PubTator, text mining | PubMed |
| Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma. | Cancer Med | 2023 | 37387466 | PubTator, text mining | PubMed |
| Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey. | JCO Precis Oncol | 2023 | 37384863 | PubTator, text mining | PubMed |
| Targeted Gene Panel Sequencing Unveiled New Pathogenic Mutations in Patients With Breast Cancer. | Bioinform Biol Insights | 2023 | 37377792 | PubTator, text mining | PubMed |
| Uncharacterized Proteins CxORFx: Subinteractome Analysis and Prognostic Significance in Cancers. | Int J Mol Sci | 2023 | 37373333 | PubTator, text mining | PubMed |
| p53 Dysregulation in Breast Cancer: Insights on Mutations in the TP53 Network and p53 Isoform Expression. | Int J Mol Sci | 2023 | 37373225 | PubTator, text mining | PubMed |
| USP15-USP7 Axis and UBE2T Differential Expression May Predict Pathogenesis and Poor Prognosis in De Novo Myelodysplastic Neoplasm. | Int J Mol Sci | 2023 | 37373211 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=25